LISRAYA Posts $31 Million Launch Quarter as Roivant Weighs Next Moves

Roivant reported $31 million in net revenue from the first five weeks of LISRAYA on the market, a figure CEO Matt Gline warned includes a boost from pharmacy inventory that was not yet dispensed to patients. The quarter closed on September 30, 2026, with $4.2 billion in cash, a net loss from continuing operations of $153 million, and roughly $280 million in stock repurchased over the prior six months. On a non-GAAP basis, the operating loss stood at $133 million. The cash balance partly reflects proceeds from Moderna litigation received over the summer.

How fast is LISRAYA actually selling?

The FDA approved LISRAYA in August for dermatomyositis. By the end of September, hundreds of patients were receiving paid drug, Gline said. By the time of the call, that figure had grown to many hundreds, with many hundreds of prescribers writing prescriptions.

Gline credited the early uptake to demand from patients and physicians. He stopped short of projecting forward. Roivant books revenue when specialty pharmacies buy the drug, not when patients receive it.

A "meaningful amount" of undispensed drug sat in specialty pharmacies on September 30, all of which has since been dispensed, Gline said. He declined to quantify the inventory contribution. It likely lifted September-quarter revenue and could create a modest headwind in the December quarter. Insurance access has generally been straightforward, though coverage policies are emerging with varying restrictions. Patients starting treatment include people switching from off-label JAK inhibitors, IVIG, steroids and immunosuppressants, plus some newly diagnosed cases.

The takeaway: five weeks of data, flattered by stocking, tells investors little about steady-state demand.

What did the rheumatoid arthritis data show?

Roivant presented results from the second period of a rheumatoid arthritis study of IMVT-1402, Immunovant's (NASDAQ:IMVT) lead-stage asset. The trial enrolled patients who had failed conventional therapy and at least two mechanisms of advanced treatment.

In the first period, all patients received 600 milligrams. Those achieving an ACR20 response — a standard measure of symptom improvement — were re-randomized to continue at 600 milligrams, drop to 300 milligrams, or take placebo. Of 118 re-randomized patients, 117 entered the efficacy analysis.

The high dose held up. At week 28:

• 92.5% of the 600-milligram group maintained an ACR20 response, versus roughly 75% on placebo, meeting the primary endpoint
• 80% of the 600-milligram group reached the stricter ACR50 threshold, versus 56% on placebo
• The 300-milligram group performed similarly to placebo

Gline said safety findings matched previously reported data, with no new signals.

Talks with the Food and Drug Administration about the next trial continue. Gline expects an update later this year or early next year, with open questions on the endpoint and whether one Phase 3 study would suffice for approval. A conventional randomized controlled trial looks more likely than another randomized-withdrawal design, he said.

Roivant is unlikely to advance IMVT-1402 in Sjögren's disease, Gline added, citing its own results and developments at other companies. It plans to finish the Phase 2 study and could reconsider if results surprise.

The takeaway: 92.5% maintenance at the high dose clears the bar; the FDA must now define what Phase 3 requires.

What else is in the pipeline?

Gline revisited prior results for brepocitinib in non-infectious uveitis, with a supplemental new drug application planned for 2027. In pulmonary hypertension associated with interstitial lung disease, mosliciguat delivered a 56% placebo-adjusted reduction in pulmonary vascular resistance at week 16 and a statistically significant 35-meter gain in six-minute walk distance. A Phase 3 study is screening and enrolling. Roivant is weighing additional indications for mosliciguat, though Gline committed to no specific new trials.

For 2027, the company expects top-line IMVT-1402 data in Graves' disease and data in myasthenia gravis. Graves' enrollment has run strong, with a timing update expected relatively soon.

Roivant plans to detail several commercial opportunities at an investor day on December 9.

The takeaway: a $4.2 billion war chest, one launched drug and three late-stage programs give management room to wait for the data.